vs
安捷伦科技（A）与Aclaris Therapeutics, Inc.（ACRS）财务数据对比。点击上方公司名可切换其他公司
安捷伦科技的季度营收约是Aclaris Therapeutics, Inc.的1388.4倍（$1.8B vs $1.3M）。安捷伦科技净利率更高（17.0% vs -1528.6%，领先1545.5%）。安捷伦科技同比增速更快（7.0% vs -85.9%）。安捷伦科技自由现金流更多（$175.0M vs $-13.2M）。过去两年安捷伦科技的营收复合增速更高（6.9% vs -26.5%）
安捷伦科技是全球知名的生命科学、诊断与应用化学领域解决方案提供商，旗下生命科学与应用市场业务板块提供液相色谱系统及组件、液相色谱质谱联用系统、气相色谱设备、电感耦合等离子体质谱仪、原子吸收仪等多种分析检测仪器，服务全球各领域客户。
Aclaris Therapeutics是一家处于临床阶段的生物制药企业，专注于研发针对免疫疾病、炎症性疾病和皮肤病的创新靶向疗法，核心管线覆盖斑秃、白癜风等未满足临床需求领域，致力于为全球相关患者提供新型治疗选择。
A vs ACRS — 直观对比
营收规模更大
A
是对方的1388.4倍
$1.3M
营收增速更快
A
高出92.9%
-85.9%
净利率更高
A
高出1545.5%
-1528.6%
自由现金流更多
A
多$188.2M
$-13.2M
两年增速更快
A
近两年复合增速
-26.5%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.8B | $1.3M |
| 净利润 | $305.0M | $-19.8M |
| 毛利率 | 52.6% | 58.9% |
| 营业利润率 | 19.6% | -1755.5% |
| 净利率 | 17.0% | -1528.6% |
| 营收同比 | 7.0% | -85.9% |
| 净利润同比 | -4.1% | 79.5% |
| 每股收益（稀释后） | $1.07 | $-0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AACRS
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $1.3M | ||
| Q3 25 | $1.7B | $3.3M | ||
| Q2 25 | $1.7B | $1.8M | ||
| Q1 25 | $1.7B | $1.5M | ||
| Q4 24 | $1.7B | $9.2M | ||
| Q3 24 | $1.6B | $4.3M | ||
| Q2 24 | $1.6B | $2.8M |
净利润AACRS
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $-19.8M | ||
| Q3 25 | $336.0M | $-14.6M | ||
| Q2 25 | $215.0M | $-15.4M | ||
| Q1 25 | $318.0M | $-15.1M | ||
| Q4 24 | $351.0M | $-96.6M | ||
| Q3 24 | $282.0M | $-7.6M | ||
| Q2 24 | $308.0M | $-11.0M |
毛利率AACRS
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | 58.9% | ||
| Q3 25 | 51.1% | 83.7% | ||
| Q2 25 | 51.9% | 71.0% | ||
| Q1 25 | 53.5% | 65.2% | ||
| Q4 24 | 53.9% | 92.3% | ||
| Q3 24 | 54.2% | 85.0% | ||
| Q2 24 | 54.4% | 77.4% |
营业利润率AACRS
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | -1755.5% | ||
| Q3 25 | 20.7% | -519.8% | ||
| Q2 25 | 18.0% | -1035.9% | ||
| Q1 25 | 22.4% | -1242.9% | ||
| Q4 24 | 24.0% | -1082.3% | ||
| Q3 24 | 21.1% | -240.9% | ||
| Q2 24 | 23.1% | -464.7% |
净利率AACRS
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | -1528.6% | ||
| Q3 25 | 19.3% | -443.0% | ||
| Q2 25 | 12.9% | -868.3% | ||
| Q1 25 | 18.9% | -1036.8% | ||
| Q4 24 | 20.6% | -1048.3% | ||
| Q3 24 | 17.9% | -174.6% | ||
| Q2 24 | 19.6% | -397.2% |
每股收益（稀释后）AACRS
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $-0.16 | ||
| Q3 25 | $1.18 | $-0.12 | ||
| Q2 25 | $0.75 | $-0.13 | ||
| Q1 25 | $1.11 | $-0.12 | ||
| Q4 24 | $1.23 | $-1.21 | ||
| Q3 24 | $0.97 | $-0.11 | ||
| Q2 24 | $1.05 | $-0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.8B | $20.0M |
| 总债务越低越好 | $3.0B | — |
| 股东权益账面价值 | $6.9B | $103.1M |
| 总资产 | $12.8B | $160.5M |
| 负债/权益比越低杠杆越低 | 0.44× | — |
8季度趋势，按日历期对齐
现金及短期投资AACRS
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $20.0M | ||
| Q3 25 | $1.5B | $25.3M | ||
| Q2 25 | $1.5B | $25.4M | ||
| Q1 25 | $1.5B | $30.4M | ||
| Q4 24 | $1.3B | $24.6M | ||
| Q3 24 | $1.8B | $47.7M | ||
| Q2 24 | $1.7B | $22.8M |
总债务AACRS
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | — | ||
| Q3 25 | $3.4B | — | ||
| Q2 25 | $3.3B | — | ||
| Q1 25 | $3.3B | — | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.1B | — |
股东权益AACRS
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $103.1M | ||
| Q3 25 | $6.4B | $120.1M | ||
| Q2 25 | $6.1B | $131.7M | ||
| Q1 25 | $6.0B | $144.1M | ||
| Q4 24 | $5.9B | $155.6M | ||
| Q3 24 | $5.9B | $130.2M | ||
| Q2 24 | $6.2B | $133.8M |
总资产AACRS
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $160.5M | ||
| Q3 25 | $12.2B | $175.5M | ||
| Q2 25 | $12.2B | $189.1M | ||
| Q1 25 | $11.9B | $198.1M | ||
| Q4 24 | $11.8B | $220.3M | ||
| Q3 24 | $11.0B | $182.4M | ||
| Q2 24 | $10.9B | $161.1M |
负债/权益比AACRS
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.53× | — | ||
| Q2 25 | 0.55× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.57× | — | ||
| Q3 24 | 0.36× | — | ||
| Q2 24 | 0.34× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $268.0M | $-13.1M |
| 自由现金流经营现金流 - 资本支出 | $175.0M | $-13.2M |
| 自由现金流率自由现金流/营收 | 9.7% | -1015.8% |
| 资本支出强度资本支出/营收 | 5.2% | 1.9% |
| 现金转化率经营现金流/净利润 | 0.88× | — |
| 过去12个月自由现金流最近4个季度 | $993.0M | $-47.2M |
8季度趋势，按日历期对齐
经营现金流AACRS
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $-13.1M | ||
| Q3 25 | $362.0M | $-10.9M | ||
| Q2 25 | $221.0M | $-10.0M | ||
| Q1 25 | $431.0M | $-13.1M | ||
| Q4 24 | $481.0M | $-8.9M | ||
| Q3 24 | $452.0M | $22.0M | ||
| Q2 24 | $333.0M | $-12.3M |
自由现金流AACRS
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $-13.2M | ||
| Q3 25 | $259.0M | $-11.0M | ||
| Q2 25 | $107.0M | $-10.0M | ||
| Q1 25 | $334.0M | $-13.1M | ||
| Q4 24 | $388.0M | — | ||
| Q3 24 | $360.0M | — | ||
| Q2 24 | $230.0M | $-12.3M |
自由现金流率AACRS
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | -1015.8% | ||
| Q3 25 | 14.9% | -332.1% | ||
| Q2 25 | 6.4% | -563.5% | ||
| Q1 25 | 19.9% | -900.3% | ||
| Q4 24 | 22.8% | — | ||
| Q3 24 | 22.8% | — | ||
| Q2 24 | 14.6% | -446.0% |
资本支出强度AACRS
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 1.9% | ||
| Q3 25 | 5.9% | 0.7% | ||
| Q2 25 | 6.8% | 1.2% | ||
| Q1 25 | 5.8% | 3.0% | ||
| Q4 24 | 5.5% | 0.0% | ||
| Q3 24 | 5.8% | 0.0% | ||
| Q2 24 | 6.5% | 0.5% |
现金转化率AACRS
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 1.03× | — | ||
| Q1 25 | 1.36× | — | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.08× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
ACRS
暂无分部数据
